ER+/HER2-乳腺癌多基因阵列检测应用：ASCO指南解读与瑞金医院临床实践

doi:10.16139/j.1007-9610.2022.05.008

外科理论与实践 ›› 2022, Vol. 27 ›› Issue (05): 416-420.doi: 10.16139/j.1007-9610.2022.05.008

ER⁺/HER2^-乳腺癌多基因阵列检测应用：ASCO指南解读与瑞金医院临床实践

舒兰, 陈小松()

上海交通大学医学院附属瑞金医院外科乳腺疾病诊治中心，上海 200025

收稿日期:2022-08-15 出版日期:2022-09-25 发布日期:2022-11-10
通讯作者: 陈小松 E-mail:chenxiaosong0156@hotmail.com

Multi-gene assay profiling testing in ER+/HER2- breast cancer: ASCO guidelinesinterpretation and Ruijin Hospital experience

SHU Lan, CHEN Xiaosong()

Received:2022-08-15 Online:2022-09-25 Published:2022-11-10
Contact: CHEN Xiaosong E-mail:chenxiaosong0156@hotmail.com

摘要/Abstract

关键词: 乳腺癌, 多基因阵列表达谱, 雌激素受体阳性/人表皮生长因子受体2阴性, ASCO指南

中图分类号:

R737.9

舒兰, 陈小松. ER⁺/HER2^-乳腺癌多基因阵列检测应用：ASCO指南解读与瑞金医院临床实践[J]. 外科理论与实践, 2022, 27(05): 416-420.

SHU Lan, CHEN Xiaosong. Multi-gene assay profiling testing in ER+/HER2- breast cancer: ASCO guidelinesinterpretation and Ruijin Hospital experience[J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 416-420.

图/表 2

参考文献 21

[1]	陈小松, 沈坤炜. 乳腺癌多基因阵列表达谱检测与个体化治疗[J]. 中华外科杂志, 2017, 55(2):99-103.
[2]	Harris LN, Ismaila N, McShane LM, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline[J]. J Clin Oncol, 2016, 34(10):1134-1150.
[3]	Krop I, Ismaila N, Andre F, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update[J]. J Clin Oncol, 2017, 35(24):2838-2847.
[4]	Andre F, Ismaila N, Henry NL, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: ASCO clinical practice guideline update—integration of results from TAILORx[J]. J Clin Oncol, 2019, 37(22):1956-1964.
[5]	Andre F, Ismaila N, Allison KH, et al. Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update[J]. J Clin Oncol, 2022, 40(16):1816-1837.
[6]	陈小松, 沈坤炜. 多基因阵列表达谱检测在乳腺癌中的应用[J]. 外科理论与实践, 2019, 24(5):412-416.
[7]	Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer[J]. N Engl J Med, 2004, 351(27):2817-2826.
[8]	陈小松, 陈舒婕, 沈坤炜. 乳腺癌的分子分型[J]. 中华肿瘤杂志, 2008, 30(9):641-643.
[9]	Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer[J]. N Engl J Med, 2018, 379(2):111-121.
[10]	Cardoso F, van′t Veer LJ, Bogaerts J, et al. 70-Gene signature as an aid to treatment decisions in early-stage breast cancer[J]. N Engl J Med, 2016, 375(8):717-729.
[11]	Sapino A, Roepman P, Linn S, et al. MammaPrint mole-cular diagnostics on formalin-fixed, paraffin-embedded tissue[J]. J Mol Diagn, 2014, 16(2):190-197.
[12]	Sparano JA, Gray RJ, Makower DF, et al. Prospective validation of a 21-gene expression assay in breast cancer[J]. N Engl J Med, 2015, 373(21):2005-2014.
[13]	Wu J, Fang Y, Lin L, et al. Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients[J]. Oncotarget, 2017, 8(24):38706-38716.
[14]	Yu J, Wu J, Huang O, et al. Clinicopathological characteristics, adjuvant chemotherapy decision and disease outcome in patients with breast cancer with a 21-gene recurrence score of 26-30[J]. Oncol Lett, 2020, 20(2):1545-1556.
[15]	Yu J, Wu J, Huang O, et al. Distribution and influence of the 21-gene recurrence score on chemotherapy decision-making in special type of breast cancer[J]. Am J Cancer Res, 2021, 11(12):6188-6199.
[16]	Sparano JA, Gray RJ, Ravdin PM, et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer[J]. N Engl J Med, 2019, 380(25):2395-2405.
[17]	Sparano JA, Gray RJ, Makower DF, et al. Clinical outcomes in early breast cancer with a high 21-gene recurrence score of 26 to 100 assigned to adjuvant chemotherapy plus endocrine therapy: a secondary analysis of the TAILORx randomized clinical trial[J]. JAMA Oncol, 2020, 6(3):367-374.
[18]	Kalinsky K, Barlow WE, Gralow JR, et al. 21-Gene assay to inform chemotherapy benefit in node-positive breast cancer[J]. N Engl J Med, 2021, 385(25):2336-2347.
[19]	Tong Y, Wu J, Huang O, et al. 21-Gene recurrence score and adjuvant chemotherapy decision for breast cancer patients with positive lymph nodes[J]. Sci Rep, 2019, 9(1):13123.
[20]	Piccart M, van′t Veer LJ, Poncet C, et al. 70-Gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age[J]. Lancet Oncol, 2021, 22(4):476-488.
[21]	Tsai M, Lo S, Audeh W, et al. Association of 70-gene signature assay findings with physicians′ treatment gui-dance for patients with early breast cancer classified as intermediate risk by the 21-gene assay[J]. JAMA Oncol, 2018, 4(1):e173470.

组织学分级	淋巴结分期	肿瘤直径（cm）	MINDACT临床危险度分级
分化较好	pN₀	≤3	临床低危
	pN₀	3.1~5	临床高危
	pN₁	≤2	临床低危
	pN₁	2.1~5	临床高危
中度分化	pN₀	≤2	临床低危
	pN₀	2.1~5	临床高危
	pN₁	任何	临床高危
分化较差	pN₀	≤1	临床低危
	pN₀	1.1~5	临床高危
	pN₁	任何	临床高危

ER⁺/HER2^-乳腺癌多基因阵列检测应用：ASCO指南解读与瑞金医院临床实践

Multi-gene assay profiling testing in ER+/HER2- breast cancer: ASCO guidelinesinterpretation and Ruijin Hospital experience

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 2

参考文献 21

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李慧, 尹昱, 李春晓, 等. 呼吸训练对乳腺癌相关淋巴水肿康复疗效的研究进展#br#[J]. 组织工程与重建外科杂志, 2023, 19(4): 430-.
[2]	张莹莹, 李华, 管佳琴, 等. 乳腺癌患者术后早期上肢淋巴水肿的发生率及影响因素分析 [J]. 组织工程与重建外科杂志, 2023, 19(3): 242-.
[3]	朱丹丽　鲍婉婷　魏昊　郭善禹. 乳腺癌术后乳房缺损修复的研究进展 [J]. 组织工程与重建外科杂志, 2023, 19(2): 201-.
[4]	朱巧俐, 苗伊鸣, 陈小松. I~III期三阴性乳腺癌病人接受保乳手术或乳房切除术的预后分析[J]. 外科理论与实践, 2023, 28(04): 371-377.
[5]	杨奕, 杨兴霞, 金思励, 张旭, 朱娟英, 陈小松. 术前MRI检查在乳腺导管原位癌保乳手术的临床应用研究[J]. 外科理论与实践, 2023, 28(04): 378-382.
[6]	董军, 崔凤鸣, 刘军. 沉默Ki-67基因对乳腺癌MCF-7/DOX细胞多柔比星耐药性的影响[J]. 外科理论与实践, 2023, 28(03): 254-259.
[7]	高卫奇, 张旭, 王铮, 朱一霏, 黄佳慧, 洪进, 朱思吉, 陈小松, 黄欧, 何建蓉, 陈伟国, 李亚芬, 沈坤炜, 徐华, 吴佳毅. 新辅助治疗后腹壁下深血管穿支皮瓣即刻乳房重建手术的安全性研究[J]. 外科理论与实践, 2023, 28(02): 147-151.
[8]	张小丽　李赞　宋达疆　王业成　海涛. 带蒂胸外侧动脉穿支皮瓣在保乳术后即刻乳房重建中的临床应用[J]. 组织工程与重建外科杂志, 2022, 18(5): 382-.
[9]	宋达疆　李赞　章一新. 带蒂腹直肌皮瓣联合游离腹壁下动脉穿支皮瓣移植重建胸壁巨大缺损的手术策略[J]. 组织工程与重建外科杂志, 2022, 18(5): 386-.
[10]	姚成才　陈明　刘长春　黄传蔷　冼家仪　严国标　陈庞洲. 硅凝胶乳房假体联合钛网补片在早期乳腺癌即刻乳房重建中的应用[J]. 组织工程与重建外科杂志, 2022, 18(3): 247-.
[11]	廖晓明　蒋奕　唐玮　杨华伟　姬逸男　韦莉颖. 薄层血管化腹股沟淋巴结皮瓣移植联合反向淋巴显影在继发性上肢淋巴水肿手术中的应用[J]. 组织工程与重建外科杂志, 2022, 18(1): 8-.
[12]	宋景涌汤鹏钟晓捷刘侠孙洋亢玉王遥佳陈安玥陈怡安吉训通周艳虹蒋曼妃修骋穆籣. 吻合口通畅性量化分析应用于乳腺癌腋窝淋巴结清扫术同期预防性淋巴管静脉吻合1例[J]. 组织工程与重建外科杂志, 2022, 18(1): 34-.
[13]	潘睿忻综述, 陈小松, 沈坤炜审校. 循环肿瘤DNA和循环肿瘤细胞检测乳腺癌微小残留病灶的研究[J]. 外科理论与实践, 2022, 27(05): 463-467.
[14]	朱思毅综述, 陈小松, 沈坤炜审校. 肥胖与早期乳腺癌预后和辅助治疗疗效的研究进展[J]. 外科理论与实践, 2022, 27(05): 468-472.
[15]	王杰强综述, 马德奎审校. Trop2基因与三阴性乳腺癌的研究进展[J]. 外科理论与实践, 2022, 27(05): 473-477.